PDF(Pubmed)
Abstract：
One-third of people with schizophrenia have elevated levels of anti-gliadin antibodies (AGA IgG). A 5-week randomized double-blind pilot study was performed in 2014-2017 in an inpatient setting to test the effect of a gluten-free diet (GFD) on participants with schizophrenia or schizoaffective disorder who also had elevated AGA IgG (≥ 20 U) but were negative for celiac disease. This earlier pilot study reported that the GFD-group showed improved gastrointestinal and psychiatric symptoms, and also improvements in TNF-α and the inflammatory cytokine IL-23. Here, we performed measurements of these banked plasma samples to detect levels of oxidative stress (OxSt) using a recently developed iridium (Ir)-reducing capacity assay. Triplicate measurements of these samples showed an Intraclass Correlation Coefficient of 0.84 which indicates good reproducibility. Further, a comparison of the OxSt measurements at the baseline and 5-week end-point for this small sample size shows that the GFD-group (N = 7) had lowered OxSt levels compared to the gluten-containing diet group (GCD; N = 9; p = 0.05). Finally, we showed that improvements in OxSt over these 5 weeks were correlated to improvements in gastrointestinal (r = +0.64, p = 0.0073) and psychiatric (r = +0.52, p = 0.039) symptoms. Also, we showed a possible association between the decrease in OxSt and the lowered levels of IL-23 (r = +0.44, p = 0.087), although without statistical significance. Thus, the Ir-reducing capacity assay provides a simple, objective measure of OxSt with the results providing further evidence that inflammation, redox dysregulation and OxSt may mediate interactions between the gut and brain.
摘要：
三分之一的精神分裂症患者的抗麦醇溶蛋白抗体（AGAIgG）水平升高。2014-2017年，在住院患者中进行了为期5周的随机双盲试点研究，以测试无麸质饮食（GFD）对精神分裂症或分裂情感障碍参与者的影响，这些参与者也有升高的AGAIgG（≥20U），但对乳糜泻呈阴性。这项较早的初步研究报告说，GFD组表现出改善的胃肠道和精神症状，以及TNF-α和炎性细胞因子IL-23的改善。这里,我们使用最近开发的铱(Ir)还原能力测定法对这些库存血浆样本进行了测量,以检测氧化应激(OxSt)水平.这些样品的三次重复测量显示0.84的组内相关系数,这表明良好的再现性。Further,对该小样本量的基线和5周终点的OxSt测量值的比较显示,与含麸质饮食组(GCD;N=9;p=0.05)相比,GFD组(N=7)的OxSt水平降低.最后,我们发现,OxSt在这5周内的改善与胃肠道症状(r=+0.64,p=0.0073)和精神病症状(r=+0.52,p=0.039)的改善相关.此外，我们显示OxSt的降低和IL-23水平的降低之间可能存在关联（r=0.44，p=0.087），虽然没有统计学意义。因此，Ir降低能力测定提供了一个简单的，OxSt的客观测量结果提供了进一步的证据，氧化还原失调和OxSt可能介导肠道和大脑之间的相互作用。
